Target intelligence / Profile preview

L-Lysyl-D-alanyl-D-alanine terminus of peptidoglycan precursor (Lys-D-Ala-D-Ala)

Target
Lys-D-Ala-D-Ala
Molecular classification
Bacterial cell wall component, Peptidoglycan precursor, Other
01

Overview

The L-Lysyl-D-alanyl-D-alanine (Lys-D-Ala-D-Ala) terminus is a critical structural component of the peptidoglycan precursor, specifically found in the cell walls of many Gram-positive bacteria (StatPearls, NBK459363). It serves as the substrate for penicillin-binding proteins (PBPs), which catalyze the cross-linking of peptidoglycan chains to provide mechanical strength to the bacterial cell wall (Nature Reviews Microbiology, 2017). This terminus is the primary molecular target for glycopeptide antibiotics, such as vancomycin and teicoplanin. These drugs bind to the D-Ala-D-Ala dipeptide with high affinity, physically blocking the enzymes responsible for cell wall assembly (PubMed, 29075017). Disruption of this process leads to weakened cell walls and eventual osmotic lysis of the bacteria. Resistance to these antibiotics often involves the modification of this target to D-Ala-D-Lac or D-Ala-D-Ser, which significantly reduces drug binding affinity (NIH, PMC4522021). This target is unique to bacteria, providing a high degree of selective toxicity for antimicrobial therapy.

Other names
D-Ala-D-Ala terminusPeptidoglycan pentapeptide terminusLipid II C-terminusD-Alanyl-D-alanine
02

Mechanism of action

Glycopeptide antibiotics bind to the D-Ala-D-Ala terminus of the peptidoglycan precursor through five hydrogen bonds. This binding sterically inhibits the transglycosylation and transpeptidation steps of cell wall synthesis, preventing the cross-linking of the peptidoglycan layer and leading to bacterial cell lysis (StatPearls, NBK459363; Nature Reviews Microbiology, 2017).

03

Biological functions

Cell wall biosynthesisPeptidoglycan cross-linkingStructural integrity maintenanceOther
04

Disease associations

Infection
05

Safety considerations

Development of glycopeptide resistance (e.g., VRE, VRSA)NephrotoxicityOtotoxicityInfusion-related reactions (Red man syndrome)
06

Interacting drugs

Vancomycin

4 more in the full profile.

07

Biomarkers

vanA gene clustervanB gene clusterD-Alanyl-D-lactate (D-Ala-D-Lac) substitutionD-Alanyl-D-serine (D-Ala-D-Ser) substitution

Beyond the preview

Go deeper on L-Lysyl-D-alanyl-D-alanine terminus of peptidoglycan precursor (Lys-D-Ala-D-Ala).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on L-Lysyl-D-alanyl-D-alanine terminus of peptidoglycan precursor (Lys-D-Ala-D-Ala).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call